Neostigmine is a cholinesterase inhibitor used in both neuromuscular and gastrointestinal conditions. It is commonly prescribed for:
∙ Myasthenia gravis, a chronic autoimmune neuromuscular disorder
∙ Reversal of non-depolarizing muscle relaxants like gallamine and tubocurarine after surgery
∙ Postoperative urinary retention or paralytic ileus, by stimulating smooth muscle contractions
Neostigmine increases the level of acetylcholine at neuromuscular junctions by inhibiting acetylcholinesterase, the enzyme responsible for breaking down acetylcholine. This results in improved muscle contraction.
Unlike some related drugs (e.g., physostigmine), neostigmine does not cross the blood-brain barrier, making it peripherally acting only.

Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Parent: Neostigmine
Impurities in neostigmine may arise from synthetic processing, storage degradation, or formulation steps. They must be controlled per ICH and pharmacopeial guidelines for drug safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Neostigmine is a cholinesterase inhibitor that: